Pomaglumetad methionil

TERMINATED · PHASE3 · Schizophrenia

The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.